Fish oils rich in n-3 fatty acids (n-3 FA) reduce serum triglyceride levels. This well known effect has been shown to be caused by decreased very low-density lipoprotein triglyceride secretion rates in kinetic studies in humans. Animal studies have explored the biochemical mechanisms underlying this effect. Triglyceride synthesis could be reduced by n-3 fatty acids in three general ways: reduced substrate (i.e. fatty acids) availability, which could be secondary to increase in b-oxidation, decreased free fatty acids delivery to the liver, decreased hepatic fatty acids synthesis; increased phospholipid synthesis; or decreased activity of triglyceride-synthesizing enzymes (diacylgylcerol acyltranferase or phosphatidic acid phosphohydrolase).
Introduction
Fish oils rich in omega-3 fatty acids (n-3 FA) have well known and long-appreciated triglyceride-lowering properties [1] . Intakes of 3-4 g of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids reduce serum triglycerides by 20-50%, depending on baseline values [2] . The mechanisms by which they accomplish this have been explored in kinetic studies in humans and animals, in perfused liver and primary hepatocytes from n-3 FA-fed animals, and in cell lines incubated with n-3 FA. Virtually universal agreement exists that n-3 FA reduce hepatic secretion of triglyceride-rich lipoproteins in humans, but the molecular mechanisms responsible for this effect (which occurs with intakes of only about 1.2% of energy from EPA þ DHA) are not clear. The purpose of this paper is to critically review the literature relating to the hepatic mechanism of action of n-3 FA as studied in the rat model (as it is by far the most common), and to assess the extent to which the findings from these studies may explain the effects seen in humans.
Effects of n-3 fatty acids on triglyceride-rich lipoprotein kinetics in humans
There have been six studies [3] [4] [5] [6] [7] [8] of the effects of n-3 FA on triglyceride metabolism in humans. All six studies found a reduced production (i.e. plasma appearance) rate of very low-density lipoprotein (VLDL) with n-3 FA consumption. Two also found increased clearance rates. The study that is perhaps the most informative (based on having the largest sample size, a relevant n-3 FA dose and patient population, the longest duration and the use of compartmental modeling) was that of Chan et al. [8] . In this study, n-3 FA (Omacor, Reliant Pharmacueticals, Liberty Corner, NJ) reduced production rates by 32% but VLDL particle clearance rates were not altered. Bordin et al.
[7] provided similar amounts of n-3 FA and reported essentially the same percentage reduction in VLDL apoB production rates. These studies firmly establish that at least part of the mechanism by which n-3 FA reduce serum triglyceride concentrations in humans by inhibiting hepatic VLDL secretion rates. [We will not address here the potential enhancement by n-3 FA of serum triglyceride clearance mechanisms (i.e. lipoprotein lipase) which may also play a role in reducing serum triglyceride concentrations [9] [10] [11] .] The consistency of the kinetic studies allows for a more focused framing of the question: what is (are) the molecular mechanism(s) by which n-3 FA reduce VLDL-triglyceride secretion from the liver? As n-3 FA feeding has not been linked with hepatic steatosis (quite the contrary), a primary effect on apo-B degradation seems unlikely (despite cell culture data suggesting it as a possibility [12, 13] ), leaving a primary effect of reduced triglyceride synthesis as the most likely candidate.
Potential mechanisms: review of biochemical pathways
VLDL triglyceride synthesis could be reduced by n3 FA by three general mechanisms:
(1) reduced substrate (i.e. FA) availability which could be secondary to: (a) an increase in beta-oxidation, whether microsomal or peroxisomal, (b) a decrease in delivery of non-esterified FA (NEFA) to the liver, or (c) a decrease in lipogenesis (i.e. FA synthesis); (2) decreased activity of triglyceride-synthesizing enzymes, such as diacylgylcerol acyltranferase (DGAT) or phosphatidic acid phosphohydrolase (PAP); or (3) increased phospholipid synthesis [which could drain diacylglycerol (DAG) away from DGAT].
Fatty acid regulation of gene transcription
The hepatic enzymes that control FA and triglyceride metabolism are obviously under transcriptional control, regulated by transcription factors which are nuclear receptors that activate/deactivate entire enzymatic pathways. How FA, especially n-3 FA, interact with these transcription factors has recently been reviewed by Jump and colleagues [14 ,15] . At least four families of transcription factors may be involved: peroxisome proliferator-activated receptor alpha (PPARa), liver X receptors, hepatic nuclear factor-4a and sterol regulatory element-binding protein-1c. These FA can also generate a bewildering array of bioactive eicosanoids via cyclo-oxygenase, lipoxygenase and mono-oxygenases [16] , and are known to influence protein kinase C activity [17 ] . The fact that both eicosanoids and protein kinase C can also modulate transcription factor activity underscores the extreme complexity of metabolic regulation. Indirect effects on gene regulation may result from alterations in lipid raft composition by n-3 FA [18] . Such mechanisms influence the activity of G-linked proteins [19] and other membrane-bound recep-tors [20 ] . A fuller discussion of these more fundamental regulatory mechanisms is, however, beyond the scope of this paper.
Methods
The goal of this paper is to review animal studies in which the effects of n-3 FA on triglyceride metabolism were explored, and to determine the extent to which consensus has been reached on any particular mechanism of action. We will evaluate whether commonly employed study designs are able, even in theory, to provide satisfactory answers to the question at hand.
Studies included
As the vast majority of animal studies that have addressed this particular question have used rats, we focused only on this species in the hope of eliminating at least one source of variation. For inclusion, the studies had to involve the following characteristics, which we deemed to be the most physiologically relevant. First, rats had to be fed with n-3 FA (whether fish oil or EPA or DHA individually). This eliminated studies in which hepatocytes from rats on standard chow were incubated with n-3 FA in vitro. Second, triglyceride metabolism in isolated hepatocytes had to be probed using non-3 FA as substrates (e.g. palmitate, oleate, linoleate or glycerol). This restriction was added because the question of the extent to which EPA or DHA themselves were oxidized or incorporated into triglycerides or phospholipid was, we felt, of little practical relevance given their low levels in the diet. What is relevant is how small amounts of these FA alter normal FA/triglyceride metabolism. We searched Medline 1966-present for omega-3 fatty acids (or fish oil or EPA or DHA), rats and triglycerides. From these studies (and others referenced in them), and after applying the inclusion criteria described above, we arrived at the set of studies summarized here (Table 1) .
Results
We located 35 publications including 42 experiments that met our inclusion criteria ( they were derived is instructive and will serve to contextualize the findings. Few investigators used study designs that would be considered physiologically relevant to humans. In 11 studies, treatment lasted less than 2 weeks, with one study examining the effects of EPA only 3 h after dosing. About half of the studies used intakes of n-3 FA of more than 3% energy (which is itself about twice the effective dose in humans). Only five used 1.5% energy or less, whereas 16 fed 6% energy or more and one provided 20% energy as n-3 FA. Only one study [36] explored all of the potential mechanisms in the same experimental setting. Not included in Table 2 are three studies in which hepatic levels of apo-B were reported to be reduced by n-3 FA feeding [31, 41, 42 ].
This effect is commonly observed in studies with cultured cell lines (as noted above), but whether this is a primary effect of n-3 FA in vivo or simply a response to a decrease in triglyceride availability is unknown.
Not cataloged in Table 2 are a variety of other, potentially relevant variations in experimental conditions encountered in these studies that could produce disparate results. These include differences in: the substrates used to test effects on FA oxidation (oleate [41] , palmitate [21, 36, 44] , lauroyl-CoA [22] or linoleate [27] ), strains of rats (Zucker obese [32, 43] , Wistar [35, 51] , Sprague Dawley [26, 49] ), physiological states (fed [43] compared with fasted [39] ) or the use of insulin to stimulate Omega-3 fatty acids lower serum triglycerides Harris and Bulchandani 389 Doses are presented as a percentage of total energy. It was calculated for each study assuming that the percentage of energy that these FA contributed to the diet was 2Â the weight percentage of these FA in the diet. EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; b-Ox, beta oxidation; DGAT, diacylglycerol acyl transferase; PAP, phosphatidic acid phosphohydrolase; sNEFA, serum non-esterified fatty acids; NT, not tested; #, decreased; ", increased; $, no effect.
lipogenesis [52] ), background dietary composition (essential FA-free [55] , types of fiber [56] , sucrose [45] ), cofactors and experimental conditions used in enzyme assays [25,39,] , the enzymes deemed representative of specific mechanistic pathways (malic enzyme [30] , tricarboxylic acid cycle [47] , acetyl-CoA carboxylase [29] ) and the methods used to infer effects of n-3 FA on enzymes when enzymatic activities were not directly measured (e.g. using the phospholipid/triglyceride ratio as a surrogate of DGAT activity [33] ).
As noted above, this review included only rats -not rabbits, hamsters, green monkeys, salmon or mice, in which similar experiments have been conducted. No studies in perfused livers have been included here (e.g. [57] ), nor studies using cultured cell lines. In the latter, significantly different conclusions may be drawn regarding the mechanism of action of n-3 FA. For example, studies in HepG2 cells typically do not report a decrease in lipogenesis [58] , the most consistent effect noted in rats (see below). What's more, it has been reported [59] that the effects of n-3 FA on hepatic triglyceride metabolism can differ significantly within the same experiment when using rat primary hepatocytes, human primary hepatocytes and cultured cell lines.
Findings of literature review
The results from these studies have been condensed and summarized in Table 3 . Given the caveats outlined above, it might be surprising that any consensus would emerge from this exercise. One effect, however, was quite consistently observed: n-3 FA feeding decreases hepatic lipogensis -FA synthesis. This was explored 16 times and found to be reduced 13 times. The three exceptions included one study [55] in which DHA was fed for 3 days compared with a linolenic acid control, and another study [29] in which lipogenesis was not decreased when measured 8 h after a single dose of either EPA or DHA. Given the extreme dissimilarity between these study designs and most of the others, we can reasonably conclude that virtually every time that n-3 FA are fed to rats, lipogenesis is inhibited. The next most consistently described effect of n-3 FA feeding was an increase in FA b-oxidation. Out of 47 experiments, 33 found it to be increased, with about half reporting increased peroxisomal oxidation and the other half mitochondrial. Notably, however, about one-third of the time, no change in b-oxidation was found. Importantly, one of the latter studies [49] utilized arguably the most relevant study design of all -1.4% EPA þ DHA fed for 6 weeks compared with a corn oil control. Another study that failed to detect a change in b-oxidation was that of Niot et al. [32] . In this trial, 0.3% energy as EPA þ DHA was provided for 7 weeks compared with a mixed-fat control diet. Here, peroxisomal FA oxidation was unaffected and mitochondrial was actually reduced. This dose (the human equivalent of about 1 g/d) would, however, be unlikely to lower serum triglyceride in humans (and its effects on rat serum triglyceride were not reported, although liver triglyceride was reduced). It should also be noted that while PPAR-a-stimulated peroxisomal FA oxidation can be substantial in rats, it may not play a significant role in humans [60] . Indeed, n-3 FA still lower serum triglyceride levels in PPAR-a knockout mice [61] . Hence, finding enhanced peroxisomal FA oxidation with n-3 FA feeding in rats may not only be irrelevant for humans, but may also occur without PPAR-a activation.
Effects on triglyceride-synthetic enzymes were mixed. In six studies in which PAP was measured, half found it to be depressed and half did not. The situation is somewhat clearer for DGAT. Its activity was measured in 17 settings, but it was reduced in only six. Hence, the weight of the evidence does not support an inhibition of these enzymes as the mechanism by which n-3 FA lower triglyceride production.
Finally, a reduction in serum NEFA could potentially reduce hepatic triglyceride synthesis. This was examined eight times and, in five, serum NEFA was indeed lowered. Evidence exists that n-3 FA inhibit hormone-sensitive lipase (in rat retroperitoneal but not subcutaneous fat [62] ); hence, a decrease in NEFA could be a primary effect. On the other hand, the very act of lowering serum triglyceride levels might be expected to result in less NEFA derived from the action of lipoprotein lipase on VLDL-triglyceride. What's more, an increase in hepatic FA extraction could also lower serum NEFA levels, but such an effect would more likely be a secondary, not a primary, effect of n-3 FA feeding, as reduced triglyceride synthesis would not logically follow increased hepatic NEFA extraction. The extent to which the supply of NEFA to the liver plays a role in the triglyceride-lowering effect of n-3 FA will require further study (Fig. 1 ).
Conclusion
Doses of 3-4 g of n-3 FA (about 1.2% of energy) clearly reduce triglyceride levels in humans by decreasing triglyceride secretion from the liver. As experimental designs have often failed to replicate the human situation, however, the molecular mechanisms by which this occurs remain uncertain. In particular, unphysiologically high doses of n-3 FA have been very commonly utilized and supplementation periods have been as short as a single dose. The clearest signal we currently have from the rat studies reviewed here is that n-3 FA decrease hepatic lipogenesis. Their effects on stimulating b-oxidation may also be relevant, but the inconsistency in this finding and the relative lack of peroxisomal oxidation in humans compared with rodents call this particular pathway into question. Therefore, it is the opinion of the authors that the mechanism of action of n-3 FA in human hepatic triglyceride metabolism remains an unanswered question.
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